Cargando…
Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors
Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) represent the most common subtype of NETs. The incidence of all NETs, and specifically GEP NETs, has risen exponentially over the last three decades. Only within the past several years have these tumors been appropriately classified, allowing...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141991/ https://www.ncbi.nlm.nih.gov/pubmed/34093744 http://dx.doi.org/10.1177/17588359211018047 |